CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 71 enrolled
Drug / intervention
FARAPULSE Endocardial Ablation Systemdevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03714178
NCT03714178N/ACompleted
CompareCT.gov

PEFCAT: A Safety and Feasibility Study of the FARAPULSE Endocardial Ablation System to Treat Paroxysmal Atrial Fibrillation

Boston Scientific Corporation·interventional·Posted Oct 22, 2018·Updated May 4, 2022

In Brief

A clinical study evaluating FARAPULSE Endocardial Ablation System for Paroxysmal Atrial Fibrillation. Completed, enrolled 71 participants across 2 sites in 2 countries.

Detailed Summary

PEFCAT is a prospective, single-arm, multi-center, safety and feasibility study evaluating the FARAPULSE Endocardial Ablation System for the treatment of paroxysmal atrial fibrillation.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsParoxysmal Atrial Fibrillation
CountriesCzechia, France
Collaborators--

Timeline

N/ACompletedFinished
20192020202120222023202420252026
First PostedOct 22, 2018
Enrollment StartOct 20, 2018
Primary CompletionDec 21, 2020
TodayJul 2, 2026
Enrollment to primary: 2.2 yearsPosted 7.7 years ago

Interventions

FARAPULSE Endocardial Ablation Systemdevice

Endocardial ablation using the FARAPULSE Endocardial Ablation System.